FCARH143 is a BCMA targeted CAR T Cell therapy being developed at the Fred Hutchinson Cancer Research Center in collaboration with Juno Therapeutics and the National Cancer Institute.
| SparkCures ID | 336 |
|---|---|
| Generic Name | FCARH143 |
| Additional Names | Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes |
| Treatment Classifications | |
| Treatment Targets |
There are no resources, links or videos to display for this treatment.